Navigation Links
Bayer Initiates Phase III Trial of Investigational Inhaled Amikacin Solution (BAY41-6551T) in Mechanically Ventilated Patients with Gram-negative Pneumonia
Date:4/16/2013

WAYNE, N.J., April 16, 2013 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals Inc. announced today that patient enrollment is underway in its global Phase III trial program to evaluate the efficacy and safety of adjunctive aerosolized BAY41-6551 versus aerosolized placebo in the treatment of intubated and mechanically ventilated patients with Gram-negative pneumonia receiving standard of care intravenous antibiotics.  BAY41-6551 consists of amikacin inhalation solution delivered by a Pulmonary Drug Delivery System (PDDS) developed by Nektar Therapeutics (NASDAQ: NKTR).

"Bayer continues to invest in research for potential treatment options for many difficult to treat diseases," said Pamela A. Cyrus , MD, Vice President and Head of U.S. Medical Affairs, Bayer HealthCare Pharmaceuticals.  "This study is designed to evaluate the effectiveness of a solution of amikacin formulated for inhalation, delivered through a proprietary drug delivery system, as an adjunctive therapy for Gram-negative pneumonia in intubated and mechanically ventilated patients."

About the Phase III INHALE Study Program
The global INHALE study program is comprised of two prospective, randomized, double-blind, placebo-controlled, multicenter studies to evaluate the safety and efficacy of BAY41-6551 as adjunctive therapy in intubated and mechanically-ventilated patients with Gram-negative pneumonia receiving standard of care intravenous antibiotics.  The study will enroll patients age 18 or above that have microbiologically-confirmed pneumonia caused by Gram-negative organisms.  INHALE will be a large multi-center global program involving centers in North America, South America, Europe, Japan, Australia and Asia.  For more information about th
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Bayer Employees Named Rising Stars by Healthcare Businesswomens Association
2. Regeneron and Bayer Announce Co-Promotion Agreement With Santen For EYLEA® (aflibercept) Injection in Japan
3. Bayer Partnership Delivers Industry-First Dose Management Offering
4. Zacks Bull and Bear of the Day Highlights: Discover Financial Services, POSCO, AstraZeneca, Bayer and Takeda Pharmaceutical
5. U.S. FDA Grants Priority Review to the New Drug Application for Bayers Regorafenib to Treat Patients with Metastatic Colorectal Cancer
6. Bayer Submits New Drug Application for Regorafenib for the Treatment of Gastrointestinal Stromal Tumors (GIST)
7. Hagens Berman Sobol Shapiro LLP and Douglas & London P.C. Announce Proposed Class Action Settlement in Bayer Combination Aspirin Products Litigation
8. MediSapiens sapprête à fournir à Bayer HealthCare Pharmaceuticals une nouvelle application informatique en nuage pour analyser et visualiser les données génomiques multidimensionnelles
9. MediSapiens liefert neue Cloud-Computing-App zur Analyse und Visualisierung multidimensionaler Genomdaten an Bayer HealthCare Pharmaceuticals
10. MediSapiens to Provide Bayer HealthCare Pharmaceuticals With a New Cloud Computing Application to Analyze and Visualize Multi-Dimensional Genomics Data
11. Bayers Second Annual Virtual Walk for Hemophilia Raises Funds, Generates Excitement in the Hemophilia Community
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014  Research and Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ) has ... - Global Industry Analysis, Size, Share, Growth, Trends And ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ... on patients in order to treat dental impairments, for ...
(Date:1/15/2014)... THOUSAND OAKS, Calif. , Jan. 15, 2014 ... and Amgen (NASDAQ: AMGN ) announced ... to jointly discover and validate new therapeutic targets ... (IBD), a chronic disorder that affects millions worldwide. ...
(Date:1/15/2014)... 2014  In an unprecedented effort to curb the spread of "superbugs" ... transport vehicles, an advanced and portable UV germicidal lamp manufactured by ... time. In order to prevent EMS paramedics and ... West Palm Beach Fire Rescue is the first ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Superbugs No Longer Ride In Rescue Vehicles 2
... Radiologist Delivers Chemo Drug Directly to Eye via,Ophthalmic ... interventional,radiology treatment successfully treats advanced retinoblastoma -- a,deadly, ... children -- and often,spares them from having their ... a study released today at the Society of,Interventional ...
... Dependent on Outcomes of New Analyses or Confirmatory ... for Tuesday March 18, 2008, BERKELEY HEIGHTS, ... ) announced that the Food and Drug,Administration,s (FDA) ... that available data are not adequate to support ...
Cached Medicine Technology:New Localized Cancer Treatment for Advanced Retinoblastoma Saves Children From Having Eyes Removed, Restores Vision in Some Cases 2New Localized Cancer Treatment for Advanced Retinoblastoma Saves Children From Having Eyes Removed, Restores Vision in Some Cases 3New Localized Cancer Treatment for Advanced Retinoblastoma Saves Children From Having Eyes Removed, Restores Vision in Some Cases 4FDA Indicates That Genasense(R) Approval in Chronic Lymphocytic Leukemia Will Require Additional Confirmatory Data 2FDA Indicates That Genasense(R) Approval in Chronic Lymphocytic Leukemia Will Require Additional Confirmatory Data 3FDA Indicates That Genasense(R) Approval in Chronic Lymphocytic Leukemia Will Require Additional Confirmatory Data 4FDA Indicates That Genasense(R) Approval in Chronic Lymphocytic Leukemia Will Require Additional Confirmatory Data 5FDA Indicates That Genasense(R) Approval in Chronic Lymphocytic Leukemia Will Require Additional Confirmatory Data 6
(Date:4/23/2014)... of Midlife Occupational and Leisure Time Physical Activity on ... activity in midlife increases the risk of mobility limitation ... risk. This is found in a study which followed ... study was conducted at the Gerontology Research Center in ... Heavy physical labor is often repetitive, wears the body ...
(Date:4/22/2014)... the United States with 1 million participants annually. A ... Injury Research and Policy at Nationwide Children,s Hospital is ... distribution patterns of basketball-related injuries treated in emergency departments ... and teens. , The study, published online in the ... to adolescents 13-19 years of age who were treated ...
(Date:4/22/2014)... 2014 Researchers at UT Southwestern Medical Center are ... depression . , A team of physician-scientists at ... ghrelin (a hormone with natural anti-depressant properties) works inside ... new treatment for depression in the form of a ... study, published online in April,s issue of Molecular ...
(Date:4/22/2014)... mice and rabbits, Johns Hopkins scientists have found a ... successfully preventing the development of atherosclerosis, the main cause ... of death among humans. The condition develops when fat ... stiff, narrowed and hardened, greatly reducing their ability to ... brain. , In a series of experiments, described April ...
(Date:4/22/2014)... LAKE CITY)A computational tool developed at the University of ... unknown gene mutations in three separate cases, U of ... study in The American Journal of Human Genetics ... tool), identifies undiagnosed illnesses and unknown gene mutations by ... that code for genes are made, in individual patients ...
Breaking Medicine News(10 mins):Health News:Midlife occupational and leisure-time physical activity limits mobility in old age 2Health News:New study finds 2.5 million basketball injuries to high school athletes in 6 seasons 2Health News:New study finds 2.5 million basketball injuries to high school athletes in 6 seasons 3Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 3Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 2Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 3Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 4Health News:Applying math to biology: Software identifies disease-causing mutations in undiagnosed illnesses 2Health News:Applying math to biology: Software identifies disease-causing mutations in undiagnosed illnesses 3
... The Company,s Commitment to Healthy and Successful Vascular ... Lifeline Vascular Access(SM), the nation,s leading provider ... its network of managed vascular access centers has ... with the Lifeline Vascular Access managed center Nephrology ...
... their full range of 7Fr IAB catheters and immediate release in the ... ... Insightra Medical Inc. , a privately held medical device company based in ... sizes including: 40cc, 35cc, 30cc, 25cc and 20cc, all in a true ...
... bleeding inside the heart after people have suffered a heart ... published today in the journal Radiology . , The ... damaged a person,s heart is after a heart attack. The ... London, hope that this kind of imaging will be used ...
... Boston, MA A collection of hospitals in eight cities ... a simple surgical checklist during major operations can lower the ... The year-long study was led by researchers from the Harvard ... Health Organization, and the results are published Online First on ...
... during breast-feeding, but resistant disease can develop in first ... -- The antiretroviral drug nevirapine may help prevent babies ... but it also greatly increases the odds of developing ... year of life, a new study finds. , Still, ...
... company, Oral BioTech, is embracing this new research on xylitol with ... Part of the motivation for these products has been the relative ... products. , ... Albany, OR (PRWEB) January 18, 2009 ...
Cached Medicine News:Health News:Lifeline Vascular Access Treats a Quarter Million Patients 2Health News:Lifeline Vascular Access Treats a Quarter Million Patients 3Health News:Insightra Medical, Inc. Gains FDA clearance for the Most Complete Range of 7Fr Intra Aortic Balloon (IAB) Catheters 2Health News:Insightra Medical, Inc. Gains FDA clearance for the Most Complete Range of 7Fr Intra Aortic Balloon (IAB) Catheters 3Health News:Bleeding hearts revealed with new scan 2Health News:Hospitals demonstrate surgical safety checklist drops deaths and complications by more than a third 2Health News:Hospitals demonstrate surgical safety checklist drops deaths and complications by more than a third 3Health News:Hospitals demonstrate surgical safety checklist drops deaths and complications by more than a third 4Health News:HIV Drug a Double-Edged Sword for Infants 2Health News:Keeping Kids Cavity-Free Before They're Ever Born: CariFree Believes Xylitol Could be This Generation's Answer 2Health News:Keeping Kids Cavity-Free Before They're Ever Born: CariFree Believes Xylitol Could be This Generation's Answer 3
Straight shafts with 1 x 2 teeth and 5 mm tying platform. Serrated handle with dull finish....
Straight shafts with 1 x 2 teeth and 6 mm tying platform. Wide serrated handle with polished finish....
Serrated, 10 mm tips angled 30 degrees. Serrated cross action handle with polished finish....
Straight shafts with 1 x 2 teeth and 6 mm tying platform. Wide smooth handle with polished finish....
Medicine Products: